



(11) **EP 2 070 920 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 72

(51) Int Cl.:
C07D 401/04 ^(2006.01) **A61K 31/445** ^(2006.01)

(48) Corrigendum issued on:
27.04.2011 Bulletin 2011/17

(45) Date of publication and mention
of the grant of the patent:
02.03.2011 Bulletin 2011/09

(21) Application number: **09151443.0**

(22) Date of filing: **24.07.1997**

(54) **Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and 1-oxoisindolines and method of reducing TNF alpha levels**

Substituierte 2-(2,6-Dioxopiperidin-3-yl)-phthalimide und Oxoisoindoline und Verfahren zur Verringerung der TNF-Alpha-Stufen

2-(2,6-dioxopiperidin-3-yl)-phthalimides et 1-oxoisindolines substituées et procédé pour réduire les niveaux de TNF alpha

(84) Designated Contracting States:
**AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC
NL PT SE**

(30) Priority: **24.07.1996 US 690258**
22.08.1996 US 701494
30.05.1997 US 48278 P

(43) Date of publication of application:
17.06.2009 Bulletin 2009/25

(60) Divisional application:
10183268.1 / 2 305 663

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
02012942.5 / 1 285 916
97936295.1 / 0 925 294

(73) Proprietor: **CELGENE CORPORATION**
Warren, NJ 07059 (US)

(72) Inventors:
• **Muller, George W**
Rancho Santa Fe, CA 92067 (US)

• **Stirling, David**
Branchburg, NJ 08876 (US)
• **Chen, Roger, Shen-Chu**
Edison, NJ 08820 (US)

(74) Representative: **Hutter, Anton et al**
Venner Shipley LLP
20 Little Britain
London
EC1A 7DH (GB)

(56) References cited:
WO-A-98/03502 US-A- 5 463 063
US-A- 5 635 517

• **NIWAYAMA S ET AL: "POTENT INHIBITION OF
TUMOR NECROSIS FACTOR-ALPHA
PRODUCTION BY
TETRAFLUOROTHALIDOMIDE AND
TETRAFLUOROPHTHALAMIDES" JOURNAL OF
MEDICINAL CHEMISTRY, AMERICAN CHEMICAL
SOCIETY, WASHINGTON., US, vol. 39, no. 16, 1
January 1996 (1996-01-01), page 3044/3045,
XP002048231 ISSN: 0022-2623**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 2 070 920 B8

- HE WEIXUAN ET AL: "Synthesis of thalidomide analogs and their biological potential for treatment of graft versus host disease." ABSTRACTS OF PAPERS AMERICAN CHEMICAL SOCIETY, vol. 206, no. 1-2, 1993, page MEDI 216, XP009001980 206th ACS; Chicago, Illinois, USA; August 22-27, 1993 ISSN: 0065-7727
- WNENDT ET AL: "Enantioselective inhibition of TNF- α . release by thalidomide and thalidomide-analogs" CHIRALITY, WILEY-LISS, NEW YORK, US, vol. 8, 1996, pages 390-396, XP002074569 ISSN: 0899-0042
- MIYACHI H ET AL: "Tumor necrosis factor- α production enhancing activity of substituted 3'-methylthalidomide: Influence of substituents at the phthaloyl moiety on the activity and stereoselectivity" CHEMICAL AND PHARMACEUTICAL BULLETIN, PHARMACEUTICAL SOCIETY OF JAPAN. TOKYO, JP, vol. 46, no. 7, July 1998 (1998-07), pages 1165-1168, XP002107774 ISSN: 0009-2363
- MULLER GEORGE W ET AL: "Amino-substituted thalidomide analogs: Potent inhibitors of TNF- α production." BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 9, no. 11, 7 June 1999 (1999-06-07), pages 1625-1630, XP004169632 ISSN: 0960-894X